The Egyptian Journal of Neurology, Psychiatry and Neurosurgery (Sep 2022)

Vertebroplasty in geriatric patients with osteoporotic vertebral fractures: single-center cohort study at a level 1 center for spinal surgery

  • Mohammed Banat,
  • Gregor Bara,
  • Abdallah Salemdawod,
  • Shaleen Rana,
  • Motaz Hamed,
  • Jasmin Scorzin,
  • Hartmut Vatter

DOI
https://doi.org/10.1186/s41983-022-00551-0
Journal volume & issue
Vol. 58, no. 1
pp. 1 – 8

Abstract

Read online

Abstract Study design Retrospective single-center cohort study. Background The spine is the most common anatomic site for osteoporotic fractures. Osteoporotic vertebral fractures play an increasingly important role in geriatric patients and percutaneous vertebroplasty (PVP) constitutes a common treatment option. The aim of this study was to evaluate the safety and efficacy of PVP in geriatric patients with cardiovascular comorbidities at our center. Methods In this retrospective single-center study, 49 patients aged ≥ 65 with a total of 88 vertebral fractures underwent vertebroplasty. MRI and CT scans of the spine were performed in all patients prior to surgery. All patients were evaluated 4 weeks after surgery as part of their clinical follow-up. VAS scores were recorded before and after the operation. Postoperative complications within 30 days of the initial surgery were analyzed. Results The mean age of patients was 77 years (± 6.4). Of the 49 patients, 39 (80%) were female, and 36 (76%) had cardiovascular comorbidities. The most frequent postoperative complications were cement leakage with no new neurological postoperative deficits (14.3%). The in-hospital mortality rate was 1 out of 49 patients (2%). VAS scores revealed an overall pain reduction of > 97%. None of the following affected patient safety: ASA, BMI, duration of surgery, or the level or localization of vertebroplasty. Conclusions Our data demonstrate that vertebroplasty was a feasible and effective treatment for pain reduction in geriatric patients with osteoporotic fractures despite cardiovascular comorbidities. Level of evidence 3.

Keywords